Susquehanna Fundamental Investments’s Bionano Genomics BNGO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-253	Closed	-$834K	–	1456
2021 Q3	$834K	Buy	253 +55	+28%	+$192K	0.02%	948
2021 Q2	$872K	Buy	+198	New	+$782K	0.02%	912

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Susquehanna Fundamental Investments's BNGO Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of Bionano Genomics (BNGO) in Q4 2021, closing a stake of 253 shares — an estimated $834K sold.

Susquehanna Fundamental Investments first reported a position in BNGO in Q2 2021 and held it in 2 quarters. The position peaked at $872K in Q2 2021. 149 funds tracked by Wall St. Rank hold BNGO as of Q4 2021.

Susquehanna Fundamental Investments reported no remaining Bionano Genomics position as of Q4 2021 after selling out during the quarter.
Susquehanna Fundamental Investments sold 253 Bionano Genomics shares in Q4 2021, an estimated $834K.
Susquehanna Fundamental Investments first reported a position in Bionano Genomics in Q2 2021 and held it in 2 quarters.
Susquehanna Fundamental Investments's Bionano Genomics position peaked at $872K in Q2 2021.
149 funds tracked by Wall St. Rank held Bionano Genomics as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.